Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.
Malard F, Labopin M, Cho C, Blaise D, Papadopoulos EB, Passweg J, O'Reilly R, Forcade E, Maloy M, Volin L, Castro-Malaspina H, Hicheri Y, Jakubowski AA, Orvain C, Giralt S, Mohty M, Nagler A, Perales MA. Malard F, et al. Among authors: hicheri y. J Hematol Oncol. 2018 Oct 20;11(1):127. doi: 10.1186/s13045-018-0668-3. J Hematol Oncol. 2018. PMID: 30342553 Free PMC article.
[ABO incompatibility and non myeloablative allogeneic stem cell transplantation].
Malfuson JV, Hicheri Y, Bonin P, Rodet M, Boccaccio C, Pautas C, Kuentz M, Cordonnier C, Noizat-Pirenne F, Maury S. Malfuson JV, et al. Among authors: hicheri y. Transfus Clin Biol. 2007 Aug;14(3):327-33. doi: 10.1016/j.tracli.2007.03.002. Epub 2007 Apr 25. Transfus Clin Biol. 2007. PMID: 17462938 Review. French.
Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire.
Mohty M, Labopin M, Balère ML, Socié G, Milpied N, Tabrizi R, Ifrah N, Hicheri Y, Dhedin N, Michallet M, Buzyn A, Cahn JY, Bourhis JH, Blaise D, Raffoux C, Espérou H, Yakoub-Agha I. Mohty M, et al. Among authors: hicheri y. Leukemia. 2010 Nov;24(11):1867-74. doi: 10.1038/leu.2010.200. Epub 2010 Sep 30. Leukemia. 2010. PMID: 20882046
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.
Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terré C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Hicheri Y, Bourhis JH, Fenaux P, Preudhomme C, Michallet M, Castaigne S, Dombret H. Thomas X, et al. Among authors: hicheri y. Blood. 2011 Aug 18;118(7):1754-62. doi: 10.1182/blood-2011-04-349258. Epub 2011 Jun 20. Blood. 2011. PMID: 21690555 Free article. Clinical Trial.
Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire.
Malard F, Milpied N, Blaise D, Chevallier P, Michallet M, Lioure B, Clément L, Hicheri Y, Cordonnier C, Huynh A, Yakoub-Agha I, Peffault de Latour R, Mohty M. Malard F, et al. Among authors: hicheri y. Biol Blood Marrow Transplant. 2015 Jun;21(6):1059-67. doi: 10.1016/j.bbmt.2015.02.014. Epub 2015 Feb 20. Biol Blood Marrow Transplant. 2015. PMID: 25708220 Free article.
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.
Cahu X, Carré M, Recher C, Pigneux A, Hunault-Berger M, Vey N, Chevallier P, Delaunay J, Gyan E, Lioure B, Bonmati C, Himberlin C, Hicheri Y, Guillerm G, Didier B, Larosa F, Ojeda-Uribe M, Bernard M, Bene MC, Ifrah N, Cahn JY. Cahu X, et al. Among authors: hicheri y. Eur J Haematol. 2017 May;98(5):443-449. doi: 10.1111/ejh.12850. Epub 2017 Mar 1. Eur J Haematol. 2017. PMID: 28122150
Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux MP, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis JH, Charbonnier A, Dauriac C, Bay JO, Blaise D, Deconinck E, Jubert C, Raus N, Peffault de Latour R, Dhedin N. Decroocq J, et al. Among authors: hicheri y. Am J Hematol. 2018 Mar;93(3):416-423. doi: 10.1002/ajh.25004. Epub 2018 Jan 8. Am J Hematol. 2018. PMID: 29226497 Free article.
Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Heinicke T, Labopin M, Schmid C, Polge E, Socié G, Blaise D, Mufti GJ, Huynh A, Brecht A, Ledoux MP, Cahn JY, Milpied N, Scheid C, Hicheri Y, Mohty M, Savani BN, Nagler A. Heinicke T, et al. Among authors: hicheri y. Biol Blood Marrow Transplant. 2018 Nov;24(11):2224-2232. doi: 10.1016/j.bbmt.2018.07.007. Epub 2018 Aug 7. Biol Blood Marrow Transplant. 2018. PMID: 30009981 Free article.
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Chiche E, Rahmé R, Bertoli S, Dumas PY, Micol JB, Hicheri Y, Pasquier F, Peterlin P, Chevallier P, Thomas X, Loschi M, Genthon A, Legrand O, Mohty M, Raffoux E, Auberger P, Caulier A, Joris M, Bonmati C, Roth-Guepin G, Lejeune C, Pigneux A, Vey N, Recher C, Ades L, Cluzeau T. Chiche E, et al. Among authors: hicheri y. Blood Adv. 2021 Jan 12;5(1):176-184. doi: 10.1182/bloodadvances.2020003159. Blood Adv. 2021. PMID: 33570629 Free PMC article.
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
Bouvier A, Hamel JF, Delaunay J, Delabesse E, Dumas PY, Ledoux MP, Peterlin P, Luquet I, Roth Guepin G, Bulabois CE, Gallego Hernanz MP, Guillerm G, Guieze R, Hicheri Y, Simand C, Himberlin C, Hunault-Berger M, Bernard M, Jourdan E, Caillot D, Dorvaux V, Tavernier E, Daguindau E, Banos A, Ojeda-Uribe M, Gyan E, Alexis M, Marolleau JP, Turlure P, Bouscary D, Humbrecht C, Zerazhi H, Béné MC, Pigneux A, Carre M, Ifrah N, Blanchet O, Vey N, Récher C, Cornillet-Lefèbvre P; French Innovative Leukemia Organization. Bouvier A, et al. Among authors: hicheri y. Eur J Haematol. 2021 Jul;107(1):111-121. doi: 10.1111/ejh.13626. Epub 2021 Apr 18. Eur J Haematol. 2021. PMID: 33765335 Clinical Trial.
66 results